Immorna receives IND clearance for Phase 1 study of self-replicating RNA-based shingles vaccine JCXH-105.
MORRISVILLE, N.C., January 9, 2023 /PRNewswire/ — Immorna, a rapidly expanding biotechnology company, focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND)…
